Stoke Therapeutics (STOK) director receives 30,782-share stock option grant

Rhea-AI Filing Summary

Stoke Therapeutics director Clare Kahn received a new stock option award covering 30,782 shares of Common Stock. The option has an exercise price of $32.79 per share and expires in 2036. It vests in 12 equal quarterly installments starting July 1, 2026, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kahn Clare

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,782	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,782 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 30,782 shares Exercise price: $32.79 per share Shares after transaction: 30,782 options +3 more

6 metrics

Option shares granted 30,782 shares Stock Option (Right to Buy) underlying Common Stock

Exercise price $32.79 per share Conversion or exercise price of the option

Shares after transaction 30,782 options Total derivative securities following the grant

Expiration date April 2, 2036 Option expiration date

Vesting start date July 1, 2026 First tranche of quarterly vesting

Vesting pattern 1/12 quarterly Vests quarterly on first day of July, October, January, April

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "32.7900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option award shall vest as to 1/12 of the total award quarterly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-04-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kahn Clare

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.79	04/03/2026		A		30,782		(1)	04/02/2036	Common Stock	30,782	$0	30,782	D

Explanation of Responses:

1. The option award shall vest as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting on July 1, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Clare Kahn report at Stoke Therapeutics (STOK)?

Clare Kahn reported receiving a stock option grant for 30,782 shares of Stoke Therapeutics Common Stock. The award is a compensation-related option, not an open-market share purchase or sale, and gives her the right to buy shares at a fixed exercise price in the future.

What are the key terms of Clare Kahn’s new stock option in STOK?

The option covers 30,782 underlying shares with a $32.79 exercise price and expires in 2036. It was granted at no cost per option share and represents a right to buy stock rather than an immediate stock purchase in the market.

How does the vesting schedule work for Clare Kahn’s Stoke Therapeutics option grant?

The option vests as to one-twelfth of the total grant quarterly on the first calendar day of July, October, January, and April. The first tranche vests July 1, 2026, and vesting requires Kahn’s continued service with Stoke Therapeutics through each vesting date.

Did Clare Kahn buy or sell any Stoke Therapeutics shares on the open market?

No open-market buys or sells were reported. The Form 4 shows a grant of a stock option award coded as an acquisition (A), which is a compensation grant. It provides potential future ownership but does not reflect a current market trade in STOK shares.

How many Stoke Therapeutics options does Clare Kahn hold after this transaction?

Following this grant, Kahn is reported as holding 30,782 stock options related to Stoke Therapeutics Common Stock. This figure reflects the awarded option position from this filing, with vesting over time and an expiration date in 2036, assuming service-based conditions are satisfied.